Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VALGANCICLOVIR HYDROCHLORIDE
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
- Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
- Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
- De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip
- CMV Immunity Monitoring in Lung Transplant Recipients
- A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Hepatocellular Carcinoma
- CMV CTLs in Neonates With CMV Infection
- Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
- Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
- Letermovir in ART-treated HIV-infected Persons
- Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
- Letermovir for CMV Prevention After Lung Transplantation
- An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
- Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
- Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1)
- ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
- A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
- Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.
- Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
- Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.
- Asymptomatic Congenital CMV Treatment
- Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma
- Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
- The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
- Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
- A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
- Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
- Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
- A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
- Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition
- Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
- Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
- ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
- Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
- Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
- Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
- CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
- Cytomegalovirus Control in Critical Care
- Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
- Tocilizumab for KSHV-Associated Multicentric Castleman Disease
- History of the KSHV Inflammatory Cytokine Syndrome (KICS)
- A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
- Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
- Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
- Antiviral Treatment of Chronic Lymphocytic Leukemia
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
- Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
- A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
- Bortezomib Plus Rituximab for EBV+ PTLD
- B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
- Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
- Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
- Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
- Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
- Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
- Alemtuzumab + Rituximab Consolidation in CLL
- Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
- Oral Valganciclovir Versus Valacyclovir
- CFAR Study in Patients With Chronic Lymphocytic Leukemia
- Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
- Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
- Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial
- VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
- Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
- TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
- A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
- Study of Prophylactic Vs Preemptive Valganciclovir
- A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
- Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
- Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
- Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
- Comparison of Sirolimus and Azathioprine in Lung Transplantation
- IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
- Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients
- The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
- WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients
- Valganciclovir to Reduce T Cell Activation in HIV Infection
- Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
- MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
- Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Suppression of Oral HHV8 Shedding With Valganciclovir
- Pharmacokinetics of Mmf and Valganciclovir
- Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
- Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
- Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
- Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients
- Valganciclovir in Congenital CMV Infants
- Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
- Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
- Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
- A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
- A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
Clinical trials list
click for details